Literature DB >> 19735674

Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding.

S Rinaldi1, K M Brennan, H J Willison.   

Abstract

Glycolipids act as receptors for a wide range of antibodies, lectins and microbes. It has long been recognised that the local topography of glycolipids in the plasma membrane is critical to these recognition events, although the biological basis for this has been relatively under-investigated. Within the last five years, emerging evidence indicates that hetero-dimeric clusters of different glycolipids can form highly distinct and specific epitopes for antibody and lectin binding. The initial observation that these ganglioside complexes (GSC) could either dramatically enhance or equally well inhibit the binding of neuropathy sera has now been reproduced for a number of other lectins, including siglecs and bacterial toxins. Here we review the initial discovery of GSC as antibody binding domains and the subsequent studies delineating their broader functional importance. Potential mechanisms underlying these effects are considered, although much remains to be investigated and explained. However, the implications for this field are potentially widespread, ranging from glycoarray design, structural biology and membrane biophysics, through to the biological consequences of glycolipid complex organisation in plasma membranes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735674     DOI: 10.1016/j.plipres.2009.09.001

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  7 in total

1.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

Review 2.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

3.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

4.  Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.

Authors:  Simon Rinaldi; Kathryn M Brennan; Gabriela Kalna; Christa Walgaard; Pieter van Doorn; Bart C Jacobs; Robert K Yu; Jan-Eric Mansson; Carl S Goodyear; Hugh J Willison
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

5.  Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes.

Authors:  Susan K Halstead; Gabriela Kalna; Mohammad B Islam; Israt Jahan; Quazi D Mohammad; Bart C Jacobs; Hubert P Endtz; Zhahirul Islam; Hugh J Willison
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-28

Review 6.  Glycoarray Technologies: Deciphering Interactions from Proteins to Live Cell Responses.

Authors:  Tania M Puvirajesinghe; Jeremy E Turnbull
Journal:  Microarrays (Basel)       Date:  2016-01-04

7.  Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders.

Authors:  Delmont Emilien; Willison Hugh
Journal:  J Neuromuscul Dis       Date:  2015-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.